Economic Aspects of Rare Diseases and Orphan Drugs

Economic difficulties related to the prevention, analysis and treatment of Rare Diseases and production of Orphan Drugs are presented compensating particular attention to the costs of financing treatment, including the issue of its repayment, which is an important and difficult to solve economic problem of the health care system. Cumulative pressures on health care financial plan have led to a rising attention in the use of economic evaluation in reimbursement decisions for Orphan Drugs and other health technologies.

  • Challenges in the economic evaluation of orphan drugs

Related Conference of Economic Aspects of Rare Diseases and Orphan Drugs

November 05-06, 2020

9th Asia Pacific STD and Infectious Diseases Congress

Tokyo, Japan
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
May 10-11, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore
September 06-07, 2021

11th World Congress on Rare Diseases and Orphan Drugs

Berlin, Germany

Economic Aspects of Rare Diseases and Orphan Drugs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in